Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald W Verhaegh

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Cancer Research|May 1, 2002
DD3(PCA3), a very sensitive and specific marker to detect prostate tumorsJacques B de Kok, Gerald W Verhaegh, Rian W Roelofs, et al.
European Journal of Orthodontics|July 15, 2023
A potential osteogenic role for microRNA-181a-5p during palatogenesisChristian Schoen, Marjon Bloemen, Carine E L Carels, et al.
Non-Coding RNA|December 22, 2022
The Androgen Regulated lncRNA <i>NAALADL2-AS2</i> Promotes Tumor Cell Survival in Prostate CancerLevi Groen, Viktor Yurevych, Harshitha Ramu, et al.
The Journal of Urology|March 31, 2021
Partial Adrenalectomy Carries a Considerable Risk of Incomplete Cure in Primary AldosteronismElle C J van de Wiel, Benno Küsters, Ritse Mann, et al.
Plos One|March 4, 2014
Prognostic relevance of urinary bladder cancer susceptibility lociAnne J Grotenhuis, Aleksandra M Dudek, Gerald W Verhaegh, et al.
European Journal of Cancer (Oxford, England : 1990)|August 29, 2006
Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancerLambertus A Kiemeney, Kjeld P van Houwelingen, Manon Bogaerts, et al.
Molecular Medicine (Cambridge, Mass.)|December 1, 2012
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancerAgus Rizal A H Hamid, Minja J Pfeiffer, Gerald W Verhaegh, et al.
Urologic Oncology|March 10, 2015
The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriersRuben G Cremers, Rosalind A Eeles, Elizabeth K Bancroft, et al.
Oral Oncology|October 20, 2022
Development and characterization of patient-derived salivary gland cancer organoid culturesGerben Lassche, Wim van Boxtel, Tilly W Aalders, et al.
Cancer Research|February 18, 2017
miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting <i>ADAM9</i> and <i>TGFBR2</i>Jasmijn G M van Kampen, Onno van Hooij, Cornelius F Jansen, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Cancer Research|May 1, 2002
DD3(PCA3), a very sensitive and specific marker to detect prostate tumorsJacques B de Kok, Gerald W Verhaegh, Rian W Roelofs, et al.
European Journal of Orthodontics|July 15, 2023
A potential osteogenic role for microRNA-181a-5p during palatogenesisChristian Schoen, Marjon Bloemen, Carine E L Carels, et al.
Non-Coding RNA|December 22, 2022
The Androgen Regulated lncRNA <i>NAALADL2-AS2</i> Promotes Tumor Cell Survival in Prostate CancerLevi Groen, Viktor Yurevych, Harshitha Ramu, et al.
The Journal of Urology|March 31, 2021
Partial Adrenalectomy Carries a Considerable Risk of Incomplete Cure in Primary AldosteronismElle C J van de Wiel, Benno Küsters, Ritse Mann, et al.
Plos One|March 4, 2014
Prognostic relevance of urinary bladder cancer susceptibility lociAnne J Grotenhuis, Aleksandra M Dudek, Gerald W Verhaegh, et al.
European Journal of Cancer (Oxford, England : 1990)|August 29, 2006
Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancerLambertus A Kiemeney, Kjeld P van Houwelingen, Manon Bogaerts, et al.
Molecular Medicine (Cambridge, Mass.)|December 1, 2012
Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancerAgus Rizal A H Hamid, Minja J Pfeiffer, Gerald W Verhaegh, et al.
Urologic Oncology|March 10, 2015
The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriersRuben G Cremers, Rosalind A Eeles, Elizabeth K Bancroft, et al.
Oral Oncology|October 20, 2022
Development and characterization of patient-derived salivary gland cancer organoid culturesGerben Lassche, Wim van Boxtel, Tilly W Aalders, et al.
Cancer Research|February 18, 2017
miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting <i>ADAM9</i> and <i>TGFBR2</i>Jasmijn G M van Kampen, Onno van Hooij, Cornelius F Jansen, et al.
Pageof 6